In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Biolinerx (BLRX), with a price target of $10.00. The company’s shares closed last Tuesday at $3.33.
According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 24.1% and a 49.3% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Global Blood Therapeutics, and Arvinas Holding Company.
Currently, the analyst consensus on Biolinerx is a Strong Buy with an average price target of $11.33, representing a 231.3% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $19.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.23 and a one-year low of $1.06. Currently, Biolinerx has an average volume of 2.64M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi’in, Israel.
Read More on BLRX:
